Genomic Health Index Score

Aliases:
This biomarker is also known as:
  • Genomic Health Index Score,
  • Oncotype DX Genomic Prostate Score,

Description…

From oncotypeiq.com: The Oncotype DX Genomic Prostate Score (GPS) assay is the only genomic assay designed for men with clinically low-risk or favorable intermediate-risk cancer to help make treatment decisions at the time of diagnosis. The assay analyzes prostate cancer gene activity to predict disease aggressiveness. It examines interactions among genes in the tumor to better understand the unique biology of the cancer—a science known as genomics—for prostate cancer patients. Essentially, the Oncotype DX GPS assay provides more specific and individualized information about prostate cancer aggressiveness based on the biology of the tumor.

Datasets

There are no datasets associated with this biomarker.

Attributes
QA State: Under Review
Type: Proteomic
HGNC Name:

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact the Informatics Center if you should have access to this biomarker.

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact the Informatics Center if you should have access to this biomarker.

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact the Informatics Center if you should have access to this biomarker.

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact the Informatics Center if you should have access to this biomarker.

Version 5.0.3